Oncology Theatre 7

Tuesday 17th March

Wednesday 18th March


11.45 - 12.15

Professor Jayant Vaidya

Targeted intraoperative radiotherapy (TARGIT-IORT) for breast cancer

Single-dose TARGeted Intraoperative radioTherapy (TARGIT-IORT) given during lumpectomy for early breast cancer within a risk-adapted approach was compared with whole breast external beam radiotherapy given over several weeks in the TARGIT-A randomised clinical trial. The published results have found that TARGIT-IORT gives similar breast cancer control and leads to fewer deaths from other causes. It is currently offered as a standard option in over 300 centers in 35 countries worldwide.


12.30 - 13.00

Malcolm Wilson

Cytoreduction and HIPEC in the treatment of peritoneal disease from appendiceal and colorectal tumours

The aim will be to give an overview in the management of peritoneal disease from both appendiceal and colorectal tumours. This will pay particular attention to the use of cytoreductive surgery and heated intra-peritoneal chemotherapy (HIPEC) and will draw on my unit’s experience of being one of the National Centres in the UK that treats this. We have performed over 1250 cases over the last 18 years and now perform 155-160 cases per year.


13.30 - 14.00

Laura Towart

Development of Personalised Treatment Recommendations for Colorectal Cancer Patients

We present a novel methodology to develop personalised therapies based on patient’s entire tumour genomes. We reconstruct cancer complexity, including several mutated cancer driver and helper genes present in the patient tumour, in the intestine of fruit flies (Drosophila). These “avatar” flies, which develop a tumour genetically similar to that of the patient, are used to screen the full FDA/EMA drug library to produce a fully tailored treatment programme.


15.00 - 15.30

Rae Denman, and Dr Zoe Poole.

Medical Tattooing: Regulating the industry

Life changing visible differences such as hair loss, scars and nipple/areola complex can arise following cancer treatments. Medical Tattooing can provide an effective treatment. Research, however, identifies; - A need for the industry to be regulated including certified training and condition specific protocols - A need for assessment procedures which ensure patient wellbeing is addressed - Improve patient referral pathway BAMT provides the relevant research based training.


15.45 - 16.15

Dr Tony Dhillon

Immunotherapy and Colon Cancer

Discussion of the evidence of benefit of checkpoint inhibition in colon cancer, in particular in the adjuvant setting- discussing on going clinical trials and up to date data. Description of data in metastatic colon cancer and future directions